NUZ-001 shows positive results in human 3D brain model
Neurizon Therapeutics Limited (“Neurizon”), a clinical-stage biotech company dedicated to advancing treatments for neurodegenerative diseases, is pleased to advise that results ...
Tag: Efficacy
Unraveling resistance to CDK4/6 inhibitors in ovarian cancer
Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, necessitating ...
Rare sugars curb appetite and mimic diabetes drugs in mice
Can rare sugars help control appetite and fight obesity? New research in mice suggests sweet solutions may lie in your ...
New peptide antibiotic stops bacteria by binding where no drug has before
Lariocidin hits drug-resistant bacteria where others fail — by hijacking the ribosome at a new site, bypassing defences, and opening ...
Targeting brain’s waste removal system may help combat cognitive decline
As aging bodies decline, the brain loses the ability to cleanse itself of waste, a scenario that scientists think could ...
Low dietary omega-3 intake linked to increased ischemic heart disease burden
New research highlights the global impact of insufficient omega-3 consumption on ischemic heart disease disability and mortality, with regional and ...
SolasCure enrols first patient in a next phase II clinical trial to advance Aurase Wound Gel
SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today announced the initiation of ...
Scientists reveal how Epstein-Barr virus reactivation triggers MIS-C in children
Why are some children devastated by mysterious post-COVID inflammation? Scientists uncover how a ‘silent’ virus awakens – and a promising ...
Unraveling the genetic differences between LUAD and LUSC in lung cancer
Lung cancer remains one of the leading causes of cancer-related mortality, with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma ...
Insilico Medicine's AI-driven drug Rentosertib receives official generic name
Insilico Medicine("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, recently announced that its breakthrough drug candidate for idiopathic ...